Literature DB >> 28148801

Inactivated Recombinant Rabies Viruses Displaying Canine Distemper Virus Glycoproteins Induce Protective Immunity against Both Pathogens.

Renata da Fontoura Budaszewski1,2, Andrew Hudacek3, Bevan Sawatsky2,4, Beate Krämer2, Xiangping Yin3, Matthias J Schnell5, Veronika von Messling6,4.   

Abstract

The development of multivalent vaccines is an attractive methodology for the simultaneous prevention of several infectious diseases in vulnerable populations. Both canine distemper virus (CDV) and rabies virus (RABV) cause lethal disease in wild and domestic carnivores. While RABV vaccines are inactivated, the live-attenuated CDV vaccines retain residual virulence for highly susceptible wildlife species. In this study, we developed recombinant bivalent vaccine candidates based on recombinant vaccine strain rabies virus particles, which concurrently display the protective CDV and RABV glycoprotein antigens. The recombinant viruses replicated to near-wild-type titers, and the heterologous glycoproteins were efficiently expressed and incorporated in the viral particles. Immunization of ferrets with beta-propiolactone-inactivated recombinant virus particles elicited protective RABV antibody titers, and animals immunized with a combination of CDV attachment protein- and fusion protein-expressing recombinant viruses were protected from lethal CDV challenge. However, animals that were immunized with only a RABV expressing the attachment protein of CDV vaccine strain Onderstepoort succumbed to infection with a more recent wild-type strain, indicating that immune responses to the more conserved fusion protein contribute to protection against heterologous CDV strains.IMPORTANCE Rabies virus and canine distemper virus (CDV) cause high mortality rates and death in many carnivores. While rabies vaccines are inactivated and thus have an excellent safety profile and high stability, live-attenuated CDV vaccines can retain residual virulence in highly susceptible species. Here we generated recombinant inactivated rabies viruses that carry one of the CDV glycoproteins on their surface. Ferrets immunized twice with a mix of recombinant rabies viruses carrying the CDV fusion and attachment glycoproteins were protected from lethal CDV challenge, whereas all animals that received recombinant rabies viruses carrying only the CDV attachment protein according to the same immunization scheme died. Irrespective of the CDV antigens used, all animals developed protective titers against rabies virus, illustrating that a bivalent rabies virus-based vaccine against CDV induces protective immune responses against both pathogens.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  antibody responses; bivalent vaccine; canine distemper virus; ferret model; rabies virus; wildlife species

Mesh:

Substances:

Year:  2017        PMID: 28148801      PMCID: PMC5375678          DOI: 10.1128/JVI.02077-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

1.  Mechanisms of loss of foreign gene expression in recombinant vesicular stomatitis viruses.

Authors:  M I Quiñones-Kochs; M J Schnell; L Buonocore; J K Rose
Journal:  Virology       Date:  2001-09-01       Impact factor: 3.616

2.  Protection of dogs against canine distemper by vaccination with a canarypox virus recombinant expressing canine distemper virus fusion and hemagglutinin glycoproteins.

Authors:  M C Pardo; J E Bauman; M Mackowiak
Journal:  Am J Vet Res       Date:  1997-08       Impact factor: 1.156

3.  Tyrosine 110 in the measles virus phosphoprotein is required to block STAT1 phosphorylation.

Authors:  Patricia Devaux; Veronika von Messling; Warangkhana Songsungthong; Christoph Springfeld; Roberto Cattaneo
Journal:  Virology       Date:  2006-11-16       Impact factor: 3.616

4.  Standardization of an enzyme immunoassay for the in vitro potency assay of inactivated tissue culture rabies vaccines: determination of the rabies virus glycoprotein with polyclonal antisera.

Authors:  O Thraenhart; K Ramakrishnan
Journal:  J Biol Stand       Date:  1989-10

5.  Vaccination against canine distemper virus infection in infant ferrets with and without maternal antibody protection, using recombinant attenuated poxvirus vaccines.

Authors:  J Welter; J Taylor; J Tartaglia; E Paoletti; C B Stephensen
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

6.  Tropism illuminated: lymphocyte-based pathways blazed by lethal morbillivirus through the host immune system.

Authors:  Veronika von Messling; Dragana Milosevic; Roberto Cattaneo
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-17       Impact factor: 11.205

7.  Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus.

Authors:  B Dietzschold; W H Wunner; T J Wiktor; A D Lopes; M Lafon; C L Smith; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

8.  Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus.

Authors:  Ryan S Noyce; Daniel G Bondre; Michael N Ha; Liang-Tzung Lin; Gary Sisson; Ming-Sound Tsao; Christopher D Richardson
Journal:  PLoS Pathog       Date:  2011-08-25       Impact factor: 6.823

9.  Phylodynamic analysis of the canine distemper virus hemagglutinin gene.

Authors:  Guan-Ming Ke; Chin-Hsiang Ho; Meng-Jung Chiang; Bintou Sanno-Duanda; Cheng-Shu Chung; Maw-Yeong Lin; Yong-Ying Shi; Ming-Hui Yang; Yu-Chang Tyan; Pao-Chi Liao; Pei-Yu Chu
Journal:  BMC Vet Res       Date:  2015-07-25       Impact factor: 2.741

Review 10.  Rabies virus as a research tool and viral vaccine vector.

Authors:  Emily A Gomme; Celestine N Wanjalla; Christoph Wirblich; Matthias J Schnell
Journal:  Adv Virus Res       Date:  2011       Impact factor: 9.937

View more
  7 in total

Review 1.  Rhabdoviruses as vectors for vaccines and therapeutics.

Authors:  Gabrielle Scher; Matthias J Schnell
Journal:  Curr Opin Virol       Date:  2020-10-29       Impact factor: 7.090

2.  A Bivalent Human Adenovirus Type 5 Vaccine Expressing the Rabies Virus Glycoprotein and Canine Distemper Virus Hemagglutinin Protein Confers Protective Immunity in Mice and Foxes.

Authors:  Lina Yan; Zhongxin Zhao; Xianghong Xue; Wenwen Zheng; Tong Xu; Lele Liu; Li Tian; Xianwei Wang; Hongbin He; Xuexing Zheng
Journal:  Front Microbiol       Date:  2020-06-16       Impact factor: 5.640

Review 3.  Tropism and molecular pathogenesis of canine distemper virus.

Authors:  Santiago Rendon-Marin; Renata da Fontoura Budaszewski; Cláudio Wageck Canal; Julian Ruiz-Saenz
Journal:  Virol J       Date:  2019-03-07       Impact factor: 4.099

4.  Probing Morbillivirus Antisera Neutralization Using Functional Chimerism between Measles Virus and Canine Distemper Virus Envelope Glycoproteins.

Authors:  Miguel Angel Muñoz-Alía; Stephen J Russell
Journal:  Viruses       Date:  2019-07-27       Impact factor: 5.048

5.  Self-assembling ferritin nanoparticles coupled with linear sequences from canine distemper virus haemagglutinin protein elicit robust immune responses.

Authors:  Bo Wang; Shuang Li; Yongbo Qiao; Yu Fu; Jiaojiao Nie; Shun Jiang; Xin Yao; Yi Pan; Linye Zhao; Congmei Wu; Yuhua Shi; Yuhe Yin; Yaming Shan
Journal:  J Nanobiotechnology       Date:  2022-01-10       Impact factor: 10.435

6.  Inactivated Rabies Virus Vectored MERS-Coronavirus Vaccine Induces Protective Immunity in Mice, Camels, and Alpacas.

Authors:  Hang Chi; Yanqun Wang; Entao Li; Xiwen Wang; Hualei Wang; Hongli Jin; Qiuxue Han; Zhenshan Wang; Xinyue Wang; Airu Zhu; Jing Sun; Zhen Zhuang; Lu Zhang; Jingmeiqi Ye; Haijun Wang; Na Feng; Mingda Hu; Yuwei Gao; Jincun Zhao; Yongkun Zhao; Songtao Yang; Xianzhu Xia
Journal:  Front Immunol       Date:  2022-01-31       Impact factor: 7.561

7.  A novel rabies vaccine based on infectious propagating particles derived from hybrid VEEV-Rabies replicon.

Authors:  Ya-Nan Zhang; Chen Chen; Cheng-Lin Deng; Cheng-Guang Zhang; Na Li; Zhen Wang; Ling Zhao; Bo Zhang
Journal:  EBioMedicine       Date:  2020-06-05       Impact factor: 8.143

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.